Citations

Clear

11 citation(s) found for "Blazar, Bruce R".

Overexpression of CD103 on regulatory T cells mitigates acute graft-versus-host disease via promotion of tolerogenic dendritic cell networks
Torghabeh, Mehrdad Hefazi, Xia, Hong , Mai, Long, Shameli, Afshin , Sirpilla, Olivia , Stewart, Carli M. , Hitosugi, Taro , DeFranco, Grace , Zhang, Shuwen , Huynh, Truc, Mangaonkar, Abhishek A. , Yun, Kun , Saleh, Ateka, Fonkoua, Lionel Aurelien Kankeu , Yamaguchi, Yoh, Foote, Sara, Goldberg, Sophia , Ruiz, Omar Gutierrez, Blazar, Bruce R., Gutierrez-Ruiz, Omar L. , Hefazi, Mehrdad , Sakemura, Reona , Kimball, Brooke , Roman, Claudia Manriquez , Stewart, Carli , Feigin, Jennifer M. , Huynh, Truc , Can, İsmail , Saleh, Ateka, Yamaguchi, Yoh, Foote, Sara, Siegler, Elizabeth L. , Kenderian, Saad S.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 587-587

10.1182/blood-2025-587 Get It

Abstract Background: Integrin αE (CD103) has been thought to mediate gut-homing Treg retention during GVHD by facilitating E-cadherin interaction on intestinal epithelial cells. However, only a small percentage of natural Tregs express CD103 in peripheral blood (PB). To leverage this mechanism and potentially enhance Treg therapeutic efficacy, we hypothesized that Tregs overexpressing CD103 (CD103high) would show improved gut-homing and GVHD mitigation. Methods: Murine CD4 Tregs were isolated from C57BL/6 (B6) mice via flow sorting and were retrovirally transduced with murine CD103 or truncated epidermal growth factor receptor as a control. Transduced Tregs were then tested in a murine acute GVHD model (B6 → BALB/c). Mouse organs, including small intestine (SI), colon, spleen, PB, axillary (aLN) and mesentric lymph nodes (mLN) were harvested on day 10 post-transplant and analyzed by flow cytometry, multiplex cytokine assay, histopathology, and single-cell RNA sequencing (scRNA-seq). Ex vivo expanded Tregs were subjected to 13C-glucose tracing assay to evaluate glycolytic flux, TCA cycle, and lipid biosynthesis. Results: Despite comparable FoxP3 expression at the end of ex vivo expansion, CD103high Tregs had significantly higher in vitro suppression compared to control Tregs (54% vs. 33% at Treg:Tcon ratio of 1:8, p=0.004). Upon re-stimulation, CD103high Tregs demonstrated increased proliferation compared to control Tregs (3.8 vs 2.8 fold expansion, p <0.0001). Bulk RNA seq on ex vivo expanded CD103high showed upregulation of immuneregulatory and metabolic programs including GTPase signaling and oxidative stress control. These transcriptomic changes suggest that CD103 intrinsically promotes a regulatory phenotype, stress tolerance and metabolic fitness. In vivo, CD103highTregs significantly decreased the severity and mortality of GVHD, compared to control Tregs, as measured by clinical scores, weight loss, and survival (50% vs 0% on day +60, p<0.0001 for three independent experiments combined; n = 24/group). Day 20 histopathology revealed significantly improved colitis scores in mice treated with CD103high Tregs vs controls (9.5 vs. 14.6, p=0.02). While these findings could be partially attributed to CD103 gut-homing function, we observed that CD103high Treg absolute number and frequency were higher not only in the the GI organs and mLN, but also in the spleen, PB, and aLN with similar distribution ratios across different organs (~5-fold higher). In vivo CFSE suppression assay, where CFSE labeled donor T cells were cotransferred with Tregs into B6 Rag1ko mice, demonstrated enhanced suppressive function of CD103high Tregs in the spleen (p=0.02), an effect that could not be accounted for by the conventional gut-homing mechanism attributed to CD103. Plasma cytokine analysis showed significantly elevated IL-10 levels in mice treated with CD103high Tregs (p<0.0001), consistent with increased Treg number and frequency. 13C-glucose tracing assay showed lower palmitate levels in CD103high Tregs, indicating lower de novo lipid synthesis, while glycolysis and TCA cycle tracing were similar. Day 10 scRNA-seq on colon samples revealed seven distinct immune clusters. The neutrophil cluster was absent in CD103high Treg group, suggesting reduced inflammation. Donor-derived dendritic cells (DCs) upregulated genes such as Cstb, and Slamf7, while pro-inflammatory genes including Cd52 and Cd74 were downregulated. STAT5 signaling was upregulated, indicating reprograming of myeloid cells toward an immunoregulatory state. Colon epithelial cells from CD103high Treg-treated mice displayed enhanced stress tolerance, with increased oxidative phosphorylation, fatty acid metabolism, and epithelial repair pathways. CellChat analysis revealed that CD103high Tregs reshaped the intestinal communication landscape, with DCs acting as key signaling hubs through interactions such as Ccl6–Ccr2 and Lgals3–Cd44. Enhanced DC-to-DC and DC-to-T cell communication suggest that CD103high Tregs promote a tolerogenic DC network that modulates downstream immune responses and supports epithelial recovery. Conclusion: Tregs overexpressing CD103 via retroviral transduction significantly improve overall survival and GVHD clinical scores in a murine transplant model. CD103High Tregs orchestrate broad remodeling of cell-cell communication across immune and stromal compartments, promoting an immunoregulatory microenvironment that underlies their protective effects in GVHD.
Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease
Ma, Lie , Koehn, Brent H. , Zaiken, Michael , Hippen, Keli L. , Smith, Kyle D. , Allred, Jeremy , Williams, Robin , Yao, Ke , Fink, Jordan , Saha, Asim , Payne, Nathaniel, Widelak, Renata, Tolar, Jakub , Xia, Lily , Witty, Alec, Mehta, Amit, Denholtz, Matthew, Hani, Sophia , Kean, Leslie S. , Valamehr, Bahram , Koehn, Brent , Tolar, Jakub , Eide, Cindy , Kenderian, Saad S. , Molldrem, Jeffrey J , Valamehr, Bahram , Blazar, Bruce R , Yao, Ke , Koop, Benjamin, Payne, Nathaniel, Panoskaltsis‐Mortari, Angela , Riddle, Megan J. , Hefazi, Mehrdad , Miller, Jeffrey S. , Molldrem, Jeffrey J. , Blazar, Bruce R.

Mayo Clinic

Blood | July 23, 2025 | Volume: 146 | Issue: 17 | Pages: 2047-2062

10.1182/blood.2025028562 | PMID 40700578 Get It

Abstract Front-line pharmaceutical interventions for treating acute graft-versus-host disease (GVHD) are not uniformly effective and have toxic side effects. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with potent in vitro and in vivo immunosuppressive functions. Clinical translation of in vitro–generated MDSCs has been limited because of requirements for multiple, high infusion doses, the relatively low yield from peripheral blood–sourced MDSCs (PB-MDSCs), and inconsistent product quality. To circumvent these obstacles, we developed a methodology to generate MDSCs using human induced pluripotent stem cell (iPSC)–derived CD34+ cells. Compared with PB-MDSCs, iPSC-derived MDSCs (iMDSCs) shared similar morphology, phenotype, and suppressive function. We found that the CD14+ iMDSC subset possessed the highest suppressor function. In previous studies, we reported that MDSCs transferred into mice with GVHD lost suppressor function because of inflammasome activation and immature myeloid cell maturation. In striking contrast to human PB-MDSCs, we show herein that iMDSCs retained 95% of suppressor function in vitro despite exposure to lipopolysaccharide (LPS) plus adenosine triphosphate (ATP), which are stimuli that activate the inflammasome via danger-associated molecular patterns released during early posttransplant conditioning and GVHD-induced injury. In an in vivo xenogenic GVHD model with PB mononuclear cells, iMDSCs significantly increased recipient survival without loss of antileukemia effects. iMDSC RNA sequencing and gene knockdown studies revealed that the maintenance of the purine metabolizing enzyme, phosphoglycerate dehydrogenase, during LPS plus ATP treatment, was linked to iMDSC inflammasome resistance. Taken together, these findings provide a platform for translating in vitro–generated, off-the-shelf iMDSCs into the clinic for suppressing a spectrum of adverse immune responses, including GVHD.
Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses
Bolivar-Wagers, Sara , Jin, Sujeong , Thangavelu, Govindarajan , Larson, Jemma H. , McDonald-Hyman, Cameron , Aguilar, Ethan G. , Saha, Asim , Koehn, Brent H. , Hefazi, Mehrdad , Osborn, Mark J. , Jensen, Michael C. , Wagner, John E. , Hefazi, Mehrdad , Koehn, Brent , Loschi, Michael L. , Pennell, Christopher A. , Blazar, Bruce R.

Mayo Clinic

JCI Insight | August 2, 2022 | Volume: 7 | Issue: 17 | Pages: No page available

10.1172/jci.insight.160674 | PMID 35917188 Get It

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) efficacy is complicated by graft-versus-host disease (GVHD), a leading cause of morbidity and mortality. Regulatory T cells (Tregs) have shown efficacy in preventing GVHD. However, high Treg doses are often required, necessitating substantial ex vivo or in vivo expansion that may diminish suppressor function. To enhance in vivo suppressor function, murine Tregs were transduced to express an anti–human CD19 chimeric antigen receptor (hCAR19) and infused into lethally irradiated, hCD19-transgenic recipients for allo-HSCT. Compared with recipients receiving control transduced Tregs, those receiving hCAR19 Tregs had a marked decrease in acute GVHD lethality. Recipient hCD19 B cells and murine hCD19 TBL12-luciferase (TBL12 luc ) lymphoma cells were both cleared by allogeneic hCAR19 Tregs, which was indicative of graft-versus-tumor (GVT) maintenance and potentiation. Mechanistically, hCAR19 Tregs killed syngeneic hCD19 + but not hCD19 – murine TBL12 luc cells in vitro in a perforin-dependent, granzyme B–independent manner. Importantly, cyclophosphamide-treated, hCD19-transgenic mice given hCAR19 cytotoxic T lymphocytes without allo-HSCT experienced rapid lethality due to systemic toxicity that has been associated with proinflammatory cytokine release; in contrast, hCAR19 Treg suppressor function enabled avoidance of this severe complication. In conclusion, hCAR19 Tregs are a potentially novel and effective strategy to suppress GVHD without loss of GVT responses.
Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases
DeFilipp, Zachariah , Chen, Yi‐Bin , Blazar, Bruce R. , Chen, Yi-Bin , Blazar, Bruce R , Hefazi, Mehrdad

Mayo Clinic

Blood | October 6, 2021 | Volume: 139 | Issue: 25 | Pages: 3583-3593

10.1182/blood.2020009014 | PMID 34614174 Get It

AbstractMany congenital or acquired nonmalignant diseases (NMDs) of the hematopoietic system can be potentially cured by allogeneic hematopoietic cell transplantation (HCT) with varying types of donor grafts, degrees of HLA matching, and intensity of conditioning regimens. Unique features that distinguish the use of allogeneic HCT in this population include higher rates of graft failure, immune-mediated cytopenias, and the potential to achieve long-term disease-free survival in a mixed chimerism state. Additionally, in contrast to patients with hematologic malignancies, a priority is to completely avoid graft-versus-host disease in patients with NMD because there is no theoretical beneficial graft-versus-leukemia effect that can accompany graft-versus-host responses. In this review, we discuss the current approach to each of these clinical issues and how emerging novel therapeutics hold promise to advance transplant care for patients with NMDs.
Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges
Bolivar-Wagers, Sara , Blazar, Bruce R. , Blazar, Bruce R , Hefazi, Mehrdad

Mayo Clinic

International Journal of Molecular Sciences | September 7, 2021 | Volume: 22 | Issue: 18 | Pages: 9676

10.3390/ijms22189676 | PMID 34575843 Get It

Graft-versus-host disease (GVHD) is the leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Immunomodulation using regulatory T cells (Tregs) offers an exciting option to prevent and/or treat GVHD as these cells naturally function to maintain immune homeostasis, can induce tolerance following HSCT, and have a tissue reparative function. Studies to date have established a clinical safety profile for polyclonal Tregs. Functional enhancement through genetic engineering offers the possibility of improved potency, specificity, and persistence. In this review, we provide the most up to date preclinical and clinical data on Treg cell therapy with a particular focus on GVHD. We discuss the different Treg subtypes and highlight the pharmacological and genetic approaches under investigation to enhance the application of Tregs in allo-HSCT. Lastly, we discuss the remaining challenges for optimal clinical translation and provide insights as to future directions of the field.
An irradiated marrow niche reveals a small non-collagenous protein mediator of homing, dermatopontin
Kramer, Ashley C. , Astuti, Yuliana, Elfstrum, Alexis K. , Lehrke, Michael Jonathan , Tolar, Jakub , Blazar, Bruce R. , Blake, Amanda L., Taisto, Mandy, Furcich, Justin W. , Nolan, Erin E. , Webber, Beau R. , Geisness, Athena , Lehrke, Michael J , Durose, Wilaiwan W , Webber, Beau R , Blazar, Bruce R , Tolar, Jakub , Wood, David K. , Lund, Troy C.

Mayo Clinic

Blood Advances | August 27, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2021004475 | PMID 34448828 Get It

Hematopoietic cell homing after hematopoietic cell transplant (HCT) is governed by several pathways involving marrow niche cells that are evoked after pre-HCT conditioning. To understand the factors that play a role in homing, we performed expression analysis on the zebrafish marrow niche cells following conditioning. We determined that the non-collagenous protein extracellular matrix related protein dermatopontin (Dpt) was upregulated seven-fold in response to irradiation. Studies in mice revealed DPT induction both with radiation and lipopolysaccharide exposure. Interestingly, we found that co-incubation of zebrafish or murine hematopoietic cells with rDPT impedes hematopoietic stem and progenitor cell homing by 50% and 86%, respectively. Similarly, this translated into a 24% reduction in long term engraftment (versus control, p = 0.01). We found DPT to interact with VLA-4 and block hematopoietic - endothelial cell adhesion and transendothelial migration. Finally, a DPT knockout mouse displayed a 60% increase in homing of hematopoietic cells versus wildtype (p = 0.03) with slight improvement in long-term LSK-SLAM engraftment (2-fold, p = 0.04). These data show that the extracellular matrix (ECM)-related protein DPT increases with radiation and transiently impedes the transendothelial migration of hematopoietic cells to the marrow.
Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802
Pidala, Joseph, Khera, Nandita , Howard, Alan , Wu, Juan , Bolaños-Meade, F. Javier, Ho, Vincent T. , Inamoto, Y., Arora, Mukta , Palmer, Jeanne , Lukez, Alexander , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Jagasia, Madan , Pusic, Iskra , Mayer, Sebastian , Renteria, Anne S. , Ayuk, Francis , Holler, Ernst , Efebera, Yvonne A. , Reantragoon, Rangsima , Yanik, Gregory A. , Ferrara, James L.M. , Holtan, Shernan G. , DeFor, Todd E. , Lee, Stephanie J. , Howard, Alan, Alousi, Amin Majid , Chen, George T , Flowers, Mary E.D. , Cutler, Corey S. , Wood, William A. , Hogan, William J. , Hexner, Elizabeth O. , Duong, Hien, Levine, John E. , Blazar, Bruce R. , Panoskaltsis‐Mortari, Angela , Weisdorf, Daniel J. , MacMillan, Margaret L.

Mayo Clinic

Blood | April 6, 2021 | Volume: 130 | Issue: Suppl_1 | Pages: 72-72

10.1182/blood.v130.suppl_1.72.72 Get It

Abstract Introduction: Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand that can restore integrity to damaged intestinal mucosa in murine models of acute graft-versus-host disease (aGVHD). We previously described AREG as a circulating biomarker of late-onset aGVHD, but its relevance combined with clinical risk factors has not yet been tested in a large cohort of patients with aGVHD occurring prior to day 100 post-transplant. We therefore tested samples from two aGVHD first-line treatment trials, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0302 and 0802, and identified a clinically relevant threshold level of circulating AREG at aGVHD onset. We then investigated whether incorporating AREG into the refined Minnesota Risk Score could further risk-stratify patients. Patients and Methods: Blood samples were obtained at the onset of systemic aGVHD treatment within BMT CTN 0302 (serum) and BMT CTN 0802 (plasma). All patients with response data and samples for analysis from both trials were included (N=251). We determined the association of AREG with clinical outcomes, including risk stratification by the refined Minnesota criteria, day 28 complete/partial response (CR/PR) to first-line therapy, 2-year overall survival (OS) and 6-month and 2-year non-relapse mortality (NRM). We investigated the effect of AREG on clinical endpoints per a doubling in the value of AREG, defined a clinically relevant threshold level in the AREG values using two-fold cross-validation, and confirmed the clinical relevance of this cut-point in independent samples (N=92) from pooled from drawn from the Chronic GVHD Consortium and the Mount Sinai Acute GVHD International Consortium (MAGIC). Results: In patients enrolled in BMT CTN 0302/0802, AREG levels were 1.7-fold higher in patients with Minnesota high-risk (HR) compared to standard-risk (SR) aGVHD (HR median 53.4 vs SR 31 pg/ml, p<0.01). Every 2-fold increase in AREG was associated with a 33% decrease in the likelihood of day 28 CR/PR (odds ratio [OR] 0.67, p<0.01, table). Clinical factors alone, as determined by the refined Minnesota Risk Score, were associated with day 28 CR/PR (p=0.02, table). Adding AREG to the Minnesota Risk Score could further risk-stratify patients. Minnesota SR patients with elevated AREG ≥ 33 pg/mL showed a 59% lower odds of day 28 CR/PR than SR patients with low AREG (OR 0.41, p=0.02). Patients with Minnesota HR aGVHD with AREG ≥ 33 pg/mL had the worst outcomes, with an 82% lower odds of day 28 CR/PR in comparison to HR with low AREG (OR 0.18, p<0.01). High AREG was associated with worse OS and NRM in both Minnesota SR (hazard ratios 2-year OS 2.3, p<0.01 and 6 month NRM 2.95, p=0.01, respectively) and HR patients (hazard ratios 2-year OS 3.35, p<0.01 and 6-month NRM 9.38, p<0.01 respectively, figure). Finally, in independent samples from the Chronic GVHD Consortium/MAGIC we confirmed that high AREG was associated with worse day 28 CR/PR (55.2% vs. 79.4%, p=0.02) and significantly worse 6-month survival after the onset of aGVHD (57.1% vs. 82.5%, p=0.01). Conclusion: AREG is elevated in patients with poor aGVHD outcomes and adds to the accuracy of risk stratification when combined with the refined Minnesota Risk Score. AREG ≥33 pg/mL at aGVHD onset is associated with lower day 28 CR/PR and higher mortality in samples from 4 multicenter cohorts. The mechanism of elevated circulating AREG in severe aGVHD is not yet known, although we hypothesize the degree of AREG elevation reflects the intensity of immune-mediated tissue injury resulting in AREG release. With accumulating evidence of altered EGFR ligands in aGVHD, further investigation into epithelial repair pathways involving AREG may lead to new adjunctive therapies to overcome poor steroid response in high-risk aGVHD. Disclosures Holtan: Incyte: Other: One-time advisory board member. Khera: Novartis: Consultancy. Lee: Mallinckrodt: Honoraria; Amgen: Other: One-time advisory board member; Bristol-Myers-Squibb: Other: One-time advisory board member; Kadmon: Other: One-time advisory board member. Chen: Immudex: Research Funding. Arora: Takeda Oncology: Consultancy. Flowers: Pharmacyclics: Consultancy. Cutler: Pfizer: Consultancy; Kite: Consultancy; Incyte: Consultancy; Bristol-Myers Squibb: Consultancy; Pharmacyclics: Consultancy; Astellas: Consultancy. Jagasia: Janssen: Consultancy, Research Funding; Therakos: Consultancy, Research Funding; Mallinckrodt: Consultancy. Hexner: Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Levine: Novartis Pharmaceuticals Corporation: Membership on an entity's Board of Directors or advisory committees. MacMillan: Magenta Therapeutics: Research Funding.
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Lee, Stephanie J. , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Bunworasate, Udomsak , Efebera, Yvonne A. , Ferrara, James L.M. , Pidala, Joseph, Howard, Alan , Wu, Juan , Bolaños‐Meade, Javier , Ho, Vincent T. , Alousi, Amin, Weisdorf, Daniel J. , MacMillan, Margaret L. , Weisdorf, Dan , Levine, John E , Holtan, Shernan , DeFor, Todd E. , Panoskaltsis‐Mortari, Angela , Flowers, Mary E.D. , Chen, George L. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Howard, Alan, Alousi, Amin Majid , Blazar, Bruce R. , Lee, Stephanie J , Wood, William A

Mayo Clinic

Blood Advances | August 28, 2018 | Volume: 2 | Issue: 15 | Pages: 1882-1888

10.1182/bloodadvances.2018017343 | PMID 30087106 Get It

Key PointsHigh-circulating AREG (≥33 pg/mL) reclassifies additional patients into HR categories and further refines the Minnesota aGVHD risk score. Patients with aGVHD and AREG ≥33 pg/mL have lower rates of steroid response, higher NRM, and poorer OS.
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Gleason, Michelle , Ross, Julie A. , Warlick, Erica D. , Wiernik, Andres , Haagenson, Michael , Lenvik, Alexander J. , Litzow, Mark R. , Epling‐Burnette, Pearlie K. , Weisdorf, Daniel J. , Vallera, Daniel A. , Miller, Jeffrey S. , Lund, Troy C. , Verneris, Michael R. , Spellman, Stephen R. , Blazar, Bruce R. , Weiner, Louis M. , Weisdorf, Dan , Miller, Jeffrey S

Mayo Clinic

Blood | March 21, 2014 | Volume: 123 | Issue: 19 | Pages: 3016-3026

10.1182/blood-2013-10-533398 | PMID 24652987 Get It

Key Points NK cells and their expression of FcRγIII (CD16) are decreased in MDS and inversely correlate with a substantial increase in MDSCs. CD16xCD33 BiKE potently activates blood and marrow MDS-NK cells at all diseases stages to lyse CD33+ MDS and CD33+ MDSC targets.
Oxygen Is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells
Olin, Michael R. , Andersen, Brian M. , Litterman, Adam J. , Grogan, Patrick T., Sarver, Aaron L. , Robertson, Paul T., Liang, Xueqing , Parney, Ian F. , Hunt, Matthew A. , Ohlfest, John R., Chen, Wei , Blazar, Bruce R. , Parney, Ian F

Mayo Clinic

Cancer Research | September 10, 2011 | Volume: 71 | Issue: 21 | Pages: 6583-6589

10.1158/0008-5472.can-11-1166 | PMID 21908554 Get It

Abstract With recent approval of the first dendritic cell (DC) vaccine for patient use, many other DC vaccine approaches are now being tested in clinical trials. Many of these DC vaccines employ tumor cell lysates (TL) generated from cells cultured in atmospheric oxygen (∼20% O2) that greatly exceeds levels found in tumors in situ. In this study, we tested the hypothesis that TLs generated from tumor cells cultured under physiologic oxygen (∼5% O2) would be more effective as a source for DC antigens. Gene expression patterns in primary glioma cultures established at 5% O2 more closely paralleled patient tumors in situ and known immunogenic antigens were more highly expressed. DCs treated with TLs generated from primary tumor cells maintained in 5% O2 took up and presented antigens to CD8 T cells more efficiently. Moreover, CD8 T cells primed in this manner exhibited superior tumoricidal activity against target cells cultured in either atmospheric 20% O2 or physiologic 5% O2. Together, these results establish a simple method to greatly improve the effectiveness of DC vaccines in stimulating the production of tumoricidal T cells, with broad implications for many of the DC-based cancer vaccines being developed for clinical application. Cancer Res; 71(21); 6583–9. ©2011 AACR.